{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-120986","form_type":"8-K","ticker":"MRKR","cik":"0001094038","company_name":"Marker Therapeutics, Inc.","filed_at":"2022-11-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.588209+00:00","generated_at":"2026-06-21T13:50:14.504846+00:00","sec_items":["7.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"FDA clears Marker Therapeutics IND for MT-601 to treat pancreatic cancer","bullets":["FDA cleared IND for MT-601, a six-antigen T cell therapy for locally advanced unresectable or metastatic pancreatic cancer.","Phase 1 trial planned for 2023, combining MT-601 with front-line chemotherapy.","New manufacturing process reduces production time from >30 days to 9 days with 90% fewer interventions.","Interim TACTOPS study data showed multiTAA therapy plus chemo yielded better-than-expected clinical responses."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-120986","json":"https://secwatch.observer/filing/0001104659-22-120986.json","markdown":"https://secwatch.observer/filing/0001104659-22-120986.md","text":"https://secwatch.observer/filing/0001104659-22-120986.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1094038/000110465922120986/0001104659-22-120986-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1094038/000110465922120986/tm2231138d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T13:50:14.504846+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}